tegilitidine

Tegilitidine (NH102) is a novel, small molecule G protein-biased mu-opioid receptor (MOR) agonist developed by Jiangsu Nhwa Pharmaceutical for the management of acute postoperative pain. It is designed to selectively activate the G protein signaling pathway, which mediates analgesia, while minimizing the recruitment of $\beta$-arrestin 2, a pathway linked to common opioid-related adverse effects such as respiratory depression, nausea, and vomiting. By decoupling these pathways, tegilitidine aims to provide a wider therapeutic window and improved safety profile compared to conventional opioids like morphine. The drug is administered intravenously and is currently being evaluated in clinical trials to determine its optimal dosing and efficacy in surgical settings.

Other names

tegilitidinetegilitidine fumarate